Published in Medicine and Law Weekly, May 19th, 2006
"The development and widespread use of DNA-based vaccination against infectious pathogens have been a great triumph of medical science. Quality control of DNA vaccines as biopharmaceutical productions is a problem to solve. Residual genomic DNA of engineering bacteria has been identified as a potential risk factor, so whose level must be controlled under the regulatory standards," scientists in China note.
"We report a dot-blot hybridization method to detect residual host cell DNA in purified DNA vaccines," announced Kai-Yu Wang and colleagues at the Second...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly